Founded in San Francisco, 1988, The Domann Organization is pleased to announce that we are entering our 35th year in the Life Sciences retained search business. Domann’s client base is primarily Venture backed Seed, Series A & B start-ups and smaller public Life Science clients who Domann worked with when pre-IPO.

Over the past 24 months we successfully completed key searches for the following private companies:

MBX Biosciences, (Independent Board Member, Chief Medical Officer, Global Vice President Regulatory)

Medikine, (President/Chief Medical Officer/Board Member)

Lengo Therapeutics, (Chief Medical Officer)

Estrigenix Therapeutics, (Executive Chair)

OnLume Surgical, (Chief Executive Officer)

ShouTi, (Senior Vice President, Biology)

Sardocor/Medera Bio (Vice President, Quality Operations, Vice President, Technical Operations)

Recent IPO public companies:

Inozyme Pharma (Senior Vice President, Technical Operations, Senior Vice President, Chief Medical Officer)

Oncolytics Biotech, (Chief Medical Officer, Executive Director, Clinical Operations, 

Executive Director, Translational Sciences, Medical Director, Clinical Development-Oncology)

Why Domann stands apart: Value creation for client, candidate, and investor. Name recognition, experience, knowledge of the Life Sciences community. Transparency, track record, network and trust.

It has been an active 24 months and we are looking forward to continuing building winning Life Science companies which make a major impact on people’s lives.

When considering search…consider Domann, Life Science leadership.

Bill Domann Email: Jovanna Bost Email: 

MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs

Financing led by Wellington Management with participation from other leading healthcare funds.

CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the closing of a $115 million Series B financing. The Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed. In addition, Tiba Aynechi, Ph. D., general partner at Norwest Venture Partners, will join the MBX board.“MBX has grown tremendously as a company since closing our Series A two years ago, including bringing our lead program MBX 2109 into the clinic, achieving proof of mechanism and now starting the multiple ascending dose portion of our Phase 1 trial,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “With the support of these leading healthcare investors, we look forward to further advancing our Precision Endocrine Peptides as part of our goal to improve outcomes and quality of life for patients with endocrine disorders.”Proceeds of the financing will support MBX into early 2025 as it develops transformative therapeutics known as Precision Endocrine Peptides (PEPs™) designed to overcome limitations of traditional peptide therapeutics. This includes continued clinical advancement of its lead product candidate, MBX 2109, which is in development for the treatment of hypoparathyroidism and currently in a Phase 1 clinical trial. In addition, proceeds will support the company’s preclinical pipeline, led by MBX 1416, and discovery programs in endocrine diseases.“We are encouraged by the progress that MBX has made to date, including advancing its PEP therapeutic candidates and building a strong team to lead the organization into the future,” said Nilesh Kumar, Ph.D., Co-Head, Biotech Private Investment at Wellington Management. “We believe the company is well positioned to bring significant benefit to patients with endocrine disorders, and we are pleased to join a great investor syndicate in supporting the company.”About MBX BiosciencesMBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, NEA, OrbiMed, Wellington Management, RA Capital Management and Norwest Venture Partners. MBX is based in Carmel, Indiana.

A Milwaukee pharmaceutical company called Estrigenix Therapeutics is getting a $300,000 federal research grant to test a potential new therapy for women with menopause.

The company yesterday announced it’s getting a one-year grant through the National Institutes of Health Small Business Innovation Research program. The funding will be used for pre-clinical studies of a drug that aims to reduce the negative symptoms of menopause while lowering the risk for dementia later in life.

According to a release from the business, when women experience declining estrogen production as they age, menopausal symptoms such as anxiety, depression, memory problems, sleep disruption and hot flashes can occur.

While existing hormone replacement therapies can help address these symptoms, Estrigenix says they can also lead to higher risk for breast cancer and strokes due to blood clots. The company is developing therapies that target specific estrogen receptors in the body in hopes of creating a “safer alternative” to traditional HRT.

Prior research conducted by Estrigenix has also shown reducing hot flashes can also lower the risk of developing dementia later on, per the release.

CEO and co-founder William Donaldson says the NIH funding represents “an important milestone” in the company’s drug development process.

“It’s exciting to see our research acknowledged and validated by such a renowned national organization that is committed to our efforts in helping women as they age,” he said in the release.

See more on the company:

See the release:

Patricia Scheller joins Estrigenix Therapeutics as Executive Chair

Patricia Scheller has over 30 years of executive experience in various healthcare industries. In addition to her role as Executive Chair of Estrigenix, she is the Chief Executive Officer and a member of the Board of Directors at Intellectual Holdings, LLC, along with a member of the Board of Directors at the non-profit Cardiovascular Institute of Philadelphia. Before this, she was the Chief Executive Officer and Board Director of Viveve, Inc. In this role, Ms. Scheller took the company from a shelved VC-backed shell to a Nasdaq-listed (VIVE) company over three years and oversaw a $100M market capitalization with nine consecutive quarters of growth. Ms. Scheller has served as a senior advisor to the Swiss government on the exportation of medical products to the United States and was the co-founder of and served as CEO and Director at Prescient Medical. Ms. Scheller received her B.S.E. in Biomedical Engineering from Duke University and completed executive business education programs at Harvard University, Massachusetts Institute of Technology, Columbia University and Northwestern University. In 2016, she received the Distinguished Alumnus Award from Duke University’s Pratt School of Engineering, the first female recipient of the award in the school’s history.